Incidence of B-CLPD with 2 or more B-cell clones within each diagnostic group for the 477 consecutively studied patients
Diagnostic group . | No. of biclonal cases/total cases . | % of cases . |
|---|---|---|
| typCLL | 12/353 | 3.4 |
| atypCLL | 4/29 | 13.8 |
| PLL | 0/5 | 0 |
| HCL | 3/13 | 23.1 |
| LPL | 0/12 | 0 |
| SMZL | 1/14 | 7.1 |
| FL | 0/22 | 0 |
| MCL | 1/19 | 5.3 |
| LCL | 2/10 | 20 |
| Total | 23/477 | 4.8 |
Diagnostic group . | No. of biclonal cases/total cases . | % of cases . |
|---|---|---|
| typCLL | 12/353 | 3.4 |
| atypCLL | 4/29 | 13.8 |
| PLL | 0/5 | 0 |
| HCL | 3/13 | 23.1 |
| LPL | 0/12 | 0 |
| SMZL | 1/14 | 7.1 |
| FL | 0/22 | 0 |
| MCL | 1/19 | 5.3 |
| LCL | 2/10 | 20 |
| Total | 23/477 | 4.8 |
typCLL versus atypCLL, P = .03; typCLL versus HCL, P = .01; typCLL versus LCL, P = .05; and HCL versus FL, P = .04. PLL indicates prolymphocytic leukemia. Other abbreviations are explained in Table 1.